Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

• Christopher M. Black,
• Glenn J. Hanna,
• Liya Wang,
• Karthik Ramakrishnan,
• Daisuke Goto,
• Vladimir Turzhitsky,
• Gleicy M. Hair

Affiliations

Christopher M. Black

Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, United States

Glenn J. Hanna

Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

Liya Wang

Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, United States

Karthik Ramakrishnan

Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, United States

Daisuke Goto

Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, United States

Vladimir Turzhitsky

Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, United States

Gleicy M. Hair

Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, United States